Stroke outcome in clinical trial patients deriving from different countries by Ali, M. et al.
 
 
 
 
 
 
 
Ali, M., Atula, S., Bath, P.M.W., Grotta, J., Hacke, W., Lyden, P., 
Marler, J.R., Sacco, R.L. and Lees, K.R. (2009) Stroke outcome in 
clinical trial patients deriving from different countries. Stroke, 40 (1). pp. 
35-40. ISSN 0039-2499 
 
http://eprints.gla.ac.uk/17635/ 
 
Deposited on: 18 January 2012 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Lyden, John R. Marler, Ralph L. Sacco and Kennedy R. Lees
Myzoon Ali, Sari Atula, Philip M.W. Bath, James Grotta, Werner Hacke, Patrick
Stroke Outcome in Clinical Trial Patients Deriving From Different Countries
ISSN: 1524-4628 
Copyright © 2008 American Heart Association. All rights reserved. Print ISSN: 0039-2499. Online
Stroke is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX 72514
doi: 10.1161/STROKEAHA.108.518035
2009, 40:35-40: originally published online October 16, 2008Stroke 
 http://stroke.ahajournals.org/content/40/1/35
located on the World Wide Web at: 
The online version of this article, along with updated information and services, is
 http://www.lww.com/reprints
Reprints: Information about reprints can be found online at 
  
 journalpermissions@lww.com
410-528-8550. E-mail: 
Fax:Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. 
Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters
  
 http://stroke.ahajournals.org//subscriptions/
Subscriptions: Information about subscribing to Stroke is online at 
 at GLASGOW UNIV LIB on January 18, 2012http://stroke.ahajournals.org/Downloaded from 
Stroke Outcome in Clinical Trial Patients Deriving From
Different Countries
Myzoon Ali, M.Res; Sari Atula, MD; Philip M.W. Bath, MD, FRCP; James Grotta, MD;
Werner Hacke, MD, PhD; Patrick Lyden, MD, FAAN; John R. Marler, MD; Ralph L. Sacco, MD, MS;
Kennedy R. Lees, MD, FRCP; for the VISTA Investigators
Background and Purpose—Stroke incidence and outcome vary widely within and across geographical locations. We
examined whether differences in index stroke severity, stroke risk factors, mortality, and stroke outcome across
geographical locations remain after adjusting for case mix.
Methods—We analyzed 3284 patients from the Virtual International Stroke Trials Archive (VISTA). We used logistic
regression to examine the incidence of mild index stroke, functional, and neurological outcomes after accounting for
age, medical history, year of trial recruitment, and initial stroke severity in the functional and neurological outcome
analyses. We examined mortality between geographical regions using a Cox proportional hazards model, accounting for
age, initial stroke severity, medical history, and year of trial recruitment.
Results—Patients enrolled in the USA and Canada had the most severe index strokes. Those recruited in Austria and
Switzerland had the best functional and neurological outcomes at 90 days (P0.05), whereas those enrolled in Germany
had the worst functional outcome at 90 days (P0.013). Patients enrolled in Austria, Switzerland, Belgium,
Netherlands, Finland, Germany, Greece, Israel, Spain, and Portugal had a significantly better survival rate when
compared with those enrolled in USA and Canada. Patients enrolled in trials after 1998 had more severe index strokes,
with no significant difference in outcome compared with those enrolled before 1998.
Conclusion—We identified regional variations in index stroke severity, outcome, and mortality for patients enrolled in
ischemic stroke clinical trials over the past 13 years that were not fully explained by case mix. Index stroke severity was
greater in patients enrolled after 1998, with no significant improvement in outcomes compared to those enrolled before
1998. (Stroke. 2009;40:35-40.)
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Worldwide, stroke is one of the leading causes of mortalityand morbidity. There are prominent variations in stroke
incidence and outcome among countries.1–3 Stroke incidence in
Asia is generally higher than in the USA.4–6 Strokes are more
frequent in Eastern than in Western Europe, with incidence
varying from 660 per 100 000 men in Russia to 303 per 100 000
men in Sweden.7 Stroke mortality is also 5-times higher in
Eastern Europe compared with Western Europe.7,8 This phe-
nomenon could also be attributed to a higher frequency of risk
factors such as hypertension and smoking9,10 in the Eastern
European population. These patients tend to have more severe
strokes, from which the recovery is poorer.
These differences are not only confined to the East–West
European axis but also are also found among the countries in
Western Europe. Stroke incidence is lower in France and the
United Kingdom compared with Germany. One-year mortal-
ity for stroke is lowest in France and highest in the United
Kingdom.7 The causes of this are still open to question but are
thought to be partially related to the variation in risk factors,
baseline characteristics of the patients, and acute stroke care
between the countries.11
Asplund et al12 reported that rehabilitation such as physiother-
apy and speech therapy was provided more often in the Neth-
erlands, Belgium, Australia, and New Zealand compared with
other regions. The standard of stroke care within countries can
vary widely.13 The availability of resources for acute stroke care
and rehabilitation can influence functional outcome and surviv-
al.14 The International Stroke Trial investigators observed the
lowest case fatality rates in Scandinavian patients, which were
thought to be attributed to the availability of acute stroke units
for these patients.15 Stroke trial centers usually deliver the
highest standards of care in the country and are associated with
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improved outcome.16 A confounding impact of stroke care on an
assessment of geographical variation in outcome should be
minimized by using patients treated in this setting. Nevertheless,
adjustment of outcome for multiple case mix and service quality
variables did not remove substantial differences in functional
outcome and death between countries in the Tinzaparin in Acute
Ischemic Stroke Trial (TAIST).17 We intended to examine the
impact of geographical location on index stroke severity, stroke
outcomes, and mortality after adjusting for case mix, among
different trial centers using the Virtual International Stroke Trials
Archive (VISTA).18
Patients and Methods
We collated anonymous data from VISTA on patients who were
recruited into clinical trials across different geographical locations.
Anonymity agreements for use of VISTA preclude identification of
the trial sources. However, we identified eligible patients who were
at least 18 years old, had documented National Institutes of Health
Stroke Scale (NIHSS), and modified Rankin Scale score available
for baseline and follow-up periods, had experienced an ischemic
stroke, previous medical history variables were available, an onset to
inclusion time was within 24 hours, and for whom no thrombolysis
or active intervention was performed. Variables of interest for our
study included baseline NIHSS score, age, sex, medical history,
geographical region, modified Rankin Scale score, and NIHSS score
Figure 1. Proportion of patients from each geographic region (a). OR for mild index stroke (NIHSS 5) among different regions
adjusted for age, medical history, and year of trial enrollment (b). OR for good functional outcome at 90 days (modified Rankin Scale
score 1) among different regions adjusted for case mix and year of trial enrollment (c). OR for good neurological outcome at 90 days
(NIHSS 1) among different regions adjusted for case mix and year of trial enrollment (d).
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at 90 days. To examine regional influences while accounting for low
sample numbers in some regions, countries within a similar geo-
graphic location were grouped together into datasets of at least 40
patients. Data from patients enrolled in the USA and Canada were
used as a reference against which we compared index stroke severity
and neurological and functional recovery in other regions, because
this group had the largest sample size and therefore offered the
strongest statistical power for comparison.
Statistical Analyses
Our primary outcome measures were the NIHSS scores at baseline and
the modified Rankin Scale score, and survival at 90 days after index
stroke. We used logistic regression to examine whether the geographical
region of trial recruitment was a significant predictor of mild index
stroke, defined as NIHSS score at baseline of5. We included age and
medical history as covariates in this model. We accounted for potential
shifts in treatment patterns over time by including a binary covariate in
our logistic regression analyses, representing patient recruitment be-
tween 1994 and 1997 or 1998 and 2000, respectively.
We defined good functional outcome at 90 days as attainment of
a modified Rankin Scale score of 1, and good neurological
outcome as attainment of a NIHSS score of 1. We performed
logistic regression using these functional and neurological outcomes
to determine whether recruitment region was a significant predictor
of good outcome after accounting for age, initial stroke severity,
medical history, and year of trial recruitment. Finally, we used a Cox
proportional hazards model to examine whether survival differed
among regions after accounting for year of recruitment, initial stroke
severity, age, and medical history.
Missing data were handled by imputing the worst possible
outcome when the patient had died within the follow-up period. All
other missing data were coded as lost to follow-up. All analyses were
performed using a SAS 9.1 statistical package.
Results
Demographic Data
We extracted anonymous data on 3284 patients who met the
stated eligibility criteria. The majority of patients in this
dataset were from USA and Canada (58%), 5% were from
Australia, New Zealand, Hong Kong, or Singapore, and 36%
were from European countries (Figure 1a). Details of case
mix across the different regions are presented in the Table.
Median age across the regions ranged from 66 (interquartile
range, 58–72) in Germany to 76 (interquartile range, 64–81)
in Greece and Israel. Median baseline NIHSS score ranged
from 10.5 (interquartile range, 6–15) in Austria and Switzer-
land to 15 (interquartile range, 10–20) in the USA and
Canada. The most frequent stroke risk factor present was
hypertension. Greece and Israel had the highest proportion of
patients with hypertension (76%) and atrial fibrillation (41%).
We accounted for the possibility that the eligibility criteria
of the original trials could confound analyses by examining
the distribution of modified Rankin Scale score across re-
gions, stratified by trial source. These distributions revealed
that eligibility criteria did not contribute to an overall differ-
ence in outcomes among the regions examined.
We first examined the variation in initial stroke severity in
patients who were recruited into clinical trials from differ-
ent regions after accounting for age, medical history, and
year of enrollment. Patients who were enrolled in Austria
and Switzerland had the mildest index stroke in our sample
(P0.0001; adjusted OR [OR] for mild stroke72.8; 95%
CI, 22.0–240.4), closely followed by patients enrolled in
Germany (P0.01; adjusted OR for mild stroke52.3; 95%
CI, 15.0–182.9; Figure 1b). In this analysis patients who were
recruited after 1998 had more severe index strokes (P0.006;
adjusted OR for mild stroke0.22; CI, 0.07–0.64).
In our analysis set only 3% of patients were lost to
follow-up at 90 days. Functional outcome at 90 days after
stroke varied by region, even after adjusting for initial stroke
severity, age, medical history, and year of enrolment. Patients
who were recruited in Austria and Switzerland attained a
significantly better functional outcome at 90 days compared
Table. Baseline Characteristics and Concomitant Diseases
Region Frequency, n Frequency, %
Age, Median
(IQR)
BNIH,
Median (IQR)
Sex,
% Male
Hemisphere,
% Right
Atrial
Fibrillation,
% Present
Hypertension,
% Present
MI,
% Present
Diabetes,
% Present
Australia & New
Zealand
102 3.1 70 (62–77) 13 (9–19) 56.9 48.0 31.4 64.0 16.3 16.7
Austria &
Switzerland
82 2.5 68 (59–77) 10.5 (6–15) 59.8 51.3 20.3 55.4 9.5 18.5
Belgium &
Netherlands
99 3.0 71 (63–78) 13 (8–18) 62.6 45.9 38.5 48.4 15.4 14.9
Denmark, Iceland,
& Norway
78 2.4 67.5 (57–73) 11 (7–16) 60.3 42.5 11.9 32.2 17.0 5.8
Finland 133 4.1 69 (64–75) 12 (7–18) 51.1 54.7 19.6 32.1 10.7 10.5
France 194 5.9 68 (55–74) 14 (10–19) 62.9 51.9 24.7 54.6 5.2 10.2
Germany 161 4.9 66 (58–72) 12 (7–15) 61.5 64.2 14.18 50.8 9.7 15.5
Greece & Israel 43 1.3 76 (64–81) 12 (7–17) 58.1 55.8 41.5 75.6 9.8 22.0
Hong Kong &
Singapore
66 2.0 74 (68–79) 12 (8–18) 48.5 43.9 40.4 66.7 3.5 28.1
Italy 130 4.0 72 (65–78) 12 (7–18) 62.3 45.4 22.1 61.1 6.2 14.4
Spain & Portugal 158 4.8 70 (64–76) 14 (9–19) 55.7 43.6 26.3 48.3 8.5 20.3
Sweden 66 2.0 73 (69–77) 13 (6–19) 74.2 47.7 33.3 43.9 15.8 21.9
UK 53 1.6 71 (64–77) 14 (8–19) 43.4 52.8 35.7 54.8 26.2 10.9
USA & Canada 1919 58.4 72 (63–79) 15 (10–20) 49.4 47.4 25.9 71.7 20.2 24.6
IQR indicates interquartile range; MI, myocardial infarction.
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with those recruited in USA and Canada (P0.023; adjusted
OR for good functional outcome1.96; 95% CI, 0.90–4.27),
closely followed by patients enrolled in Italy (P0.036;
adjusted OR for good functional outcome1.78; 95% CI,
0.85–3.75). Patients recruited in Germany had a significantly
worse functional outcome at 90 days (P0.013; adjusted OR
for good functional outcome0.31; 95% CI, 0.13–0.76;
Figure 1c). Trial recruitment after 1998 was not a significant
predictor of good functional outcome at 90 days (P0.42).
Patients enrolled in Austria and Switzerland had a signif-
icantly better neurological outcome at 90 days (P0.034;
adjusted OR for good neurological outcome2.42; 95% CI,
1.08–5.41) when compared with those enrolled in the USA
and Canada (Figure 1 d). Likewise, trial recruitment after
1998 was not a significant predictor of good neurological
outcome at 90 days (P0.87).
We examined survival at 90 days after acute ischemic
stroke to determine if mortality varied between geographical
locations after adjusting for case mix. A Cox proportional
hazards model showed that patients enrolled in Australia,
New Zealand, Austria, Switzerland, Belgium, Netherlands,
Finland, Germany, Greece, Israel, Spain, and Portugal had a
significantly better survival rate when compared with those
enrolled in USA and Canada (P0.05; Figure 2), with those
enrolled in Spain and Portugal having the best survival rate in
our sample (P0.0001; hazard ratio for survival1.70; 95%
CI, 1.31–2.20).
Discussion
Investigating stroke incidence in different parts of the world
increases our understanding of etiology and prevention.19
Epidemiological studies form the basis for future research;20
knowledge of disease patterns and regional differences assist
the targeting of programs that could help reduce risk factors
and distribute resources for stroke management.21 We aimed
to identify region specific differences in index stroke, out-
come, and mortality after accounting for case mix.
In our analysis set, patient observations from some coun-
tries were underrepresented; therefore, some analyses lacked
power. We overcame this by grouping countries together
according to geographical location. We recognize that the
participating centers may represent some of the more orga-
nized hospitals in their country and that this may diminish
country-specific differences; however, this strengthens rather
than weakens our conclusions as the impact of standard of
care on outcome is minimized.
After accounting for initial stroke severity, age, year of
recruitment, and medical history, we found that trial recruit-
ment in Austria, Switzerland, and Italy was a significant
predictor of good functional outcome at 90 days when
compared with the USA and Canada (P0.05). This trend
toward better recovery was also reflected in the neurological
outcomes of patients recruited in Austria and Switzerland
(P0.03). Adjustment for period of trial recruitment revealed
a trend for more severe stroke in trials conducted after 1998,
with no improvement in functional or neurological outcome
when compared with earlier trials. This may be a reflection of
the increasing severity of index stroke after 1998, along with
the lack of clinical impact of new drugs since the licensing of
recombinant tissue plasminogen activator.22 Moreover, it is
possible that the increased use of recombinant tissue plasmin-
ogen activator within the 3-hour time window could have led
to some selection of patients with more severe cases for trials
after 1998. Survival across the different regions varied, with
patients enrolled in Australia, New Zealand, Austria, Swit-
zerland, Belgium, Netherlands, Finland, Germany, Greece,
Figure 2. Hazard ratio for survival at 90
days among different regions adjusted for
case mix and year of trial enrollment.
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Israel, Spain, and Portugal all reporting a significantly better
survival rate than those enrolled in USA and Canada.
Our dataset did not contain any patients who were enrolled
in the Far East or South America. Our findings are therefore
only applicable to a subset of stroke trial patients; these are
typical of internationally conducted trials over the last de-
cade. Disparity in outcome could be partially explained by
variations in stroke care17 per capita expenditure on health
care, health care policy, and availability of rehabilitation
resources among the regions examined. It has been previously
documented that dedicated stroke units can reduce disabili-
ty.16 For example, the Scandinavian stroke unit model com-
bines both acute and rehabilitation stroke units nationwide,
and this was reflected in low case fatality.23 However, not all
stroke patients have access to these units.17 Despite the
established benefits, it is still uncommon for patients to be
admitted into stroke units in many Italian regions; patients are
most commonly admitted into general wards.24 The propor-
tion of patients who receive brain imaging, neurosurgery,
physiotherapy, speech therapy, and occupational therapy25
and the degree of governmental expenditure on health care
can influence outcome. For example, the United States
government in 2003 spent USD $2548 per capita on health
care. In contrast, government expenditure on health care in
Singapore in 2003 was USD $348.26 Distribution of health
care workers also differ among regions, with Belgium report-
ing a greater number of physicians per 1000 people (4.49)
compared with Canada (2.13).27 These factors in combination
can impact the standards of care available and contribute to
disparity. We lacked data on the standard of stroke care
available to each patient and therefore could not consider this
as a covariate in this analysis.
Although we noted a variation in functional outcome at 90
days between different regions, we are unable to draw
inferences regarding its cause. Data on socioeconomic status,
a predictor of stroke both in poor and developed coun-
tries,28–30 were not available and may have influenced out-
come. Socioeconomical factors are complex in their nature
and influence both risk factors and standards of care.28,31 Risk
factors vary across the lifespan and show regional and
international variations.21 Recording of patient lifestyle is
imperfect in its nature and, particularly in our series, some
lifestyle and social factors that may have impacted outcome,
such as the degree of family support available,32 were not
recorded. This may have confounded our results. In addition,
factors such as ethnicity33–35 and stroke subtype may have had
an impact on outcome in our sample. Both stroke subtype and
ethnicity were not included as covariates in our analyses but
should be taken into account when interpreting outcome.
We found significant differences in mortality in many
European countries compared with the USA and Canada.
This finding was supported by Asplund et al,12 Gray et al,36
and Holland.37 Both Grieve et al38 and Holland37 reported that
stroke outcome was worst in the UK. Our findings are
congruent with these investigations. We found no significant
difference in the outcome or survival of patients enrolled in
the UK compared with those recruited in the USA and
Canada, which had the worst survival rate in our study. Our
mortality results could also be explained by the use of optimal
patient selection during the trial recruitment phase; the trials
may have excluded patients with a poorer prognosis.
Sudlow et al19 reported that comparisons of stroke inci-
dence in different regions are only meaningful if investiga-
tions use standard definitions and methods. The strengths of
our analysis lay in the robust data collection protocols
implemented within VISTA and the depth of patients vari-
ables available. However, data were extracted from trials that
were primarily concerned with the treatment of ischemic
stroke using a novel therapy and, as such, data collection was
not specifically tailored for an epidemiological investigation.
Numerous socioeconomic factors that impact stroke recovery
were not recorded within VISTA.
We conclude that recruitment in recent trials was associated
with more severe index stroke, but not with significant differ-
ence in outcome when compared with earlier trial enrolment.
Variation in stroke outcome across different geographical re-
gions was evident after adjustment for case mix. Patients
recruited in the USA and Canada had the worst index stroke
severity. Patients recruited in Austria and Switzerland had the
best functional and neurological outcome at 90 days after
adjusting for case mix. Patients enrolled in Spain and Portugal
had the best survival rate. Because the differences in outcome
between countries are larger than the expected treatment effects
of some interventions, the findings here echo the need for
rigorous randomization practices for active and control groups
within multinational trials to avoid false treatment effects in
regions where placebo-treated patients achieve a good outcome
after accounting for case mix.39 Our findings may be pertinent to
trials that do not include ethnicity or country of recruitment as a
covariate in analyses. We consider it unlikely that these findings
would explain discrepant results between consecutive trials of
the same drugs, for example, the Lubeluzole North American
trial,40 and the subsequent neutral European Lubeluzole trial,41
or the failure of SAINT II compared with SAINT I.42 These
trials randomized patients within centers or countries and some
included geographical site or country as a covariate in analy-
sis;42,43 overall, severity and outcomes were similar between
trials.
Further investigation of the causes of regional differences
in outcome would be beneficial particularly in developing
countries that are underrepresented within VISTA. This could
include an investigation of stroke subtypes, time from stroke
onset to treatment, the underlying socioeconomic influences,
and access to and use of health care resources within
countries that have reported a poorer outcome. Additionally,
more emphasis on risk factor reduction, secondary preven-
tion, and rehabilitation may redress the changes in stroke
severity and outcome observed in our time course analysis.
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